Could this treatment free liver transplant patients from lifelong medications?

NCT ID NCT06832189

Summary

This early-stage study is testing whether a combination of two drugs (everolimus and epoetin) can help stable liver transplant recipients safely reduce and potentially stop their lifelong anti-rejection medications. The goal is to help patients achieve 'operational tolerance' where their body accepts the transplanted liver without needing constant immune suppression. Researchers will carefully monitor 20 participants for safety and whether they can maintain stable liver function while reducing medications.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Northwestern University Feinberg School of Medicine

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California San Francisco School of Medicine

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pennsylvania Medical Center

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.